Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Associations Between Previously Identified Genetic Variants and Clinical Phenotypes of Diabetic Neuropathy in Type 2 Diabetes: An Exploratory Analysis of the Discovery Cohort.

International journal of molecular sciences·2026

Same author

Non-Invasive Monitoring of Hemodialysis Patients: Challenges and Benefits in the Real World.

Clinics and practice·2026

Same author

Trends in Gestational Diabetes Identified through Universal Screening: A Population-Based Observational Study.

BJOG : an international journal of obstetrics and gynaecology·2026

Same author

Age- and cognitive load-related variability and entropy of gait: integrating coefficient of variation, median absolute deviation, and permutation entropy of spatiotemporal parameters into the Semmelweis Study gait assessment framework.

GeroScience·2026

Same author

Induced Circular Dichroism From the Binding of Achiral Bivalent Ligands to Transthyretin.

Journal of molecular recognition : JMR·2026

Same author

Metasurface analogues of molecular diastereomers from hierarchical multiscale chiral interactions with biomolecules.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose management indicator: Do we need device-specific equations?

Tamás Jávorfi¹, Győző Kocsis², Márk M Svébis¹

¹Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, Budapest, Hungary; Károly Rácz Conservative Medicine Division, Doctoral College, Semmelweis University, Budapest, Hungary.

Diabetes & Metabolism

|May 8, 2025

Summary

Device-specific Glucose Management Indicator (GMI) equations for Guardian 3 and 4 continuous glucose monitoring (CGM) systems improve HbA1c estimation accuracy. These tailored GMIs reduce significant glycaemic under- and overestimations in type 1 diabetes management.

Keywords:

Continuous Glucose Monitoring Diabetes Mellitus, Type 1 Glucose Management Indicator Glycated Hemoglobin Glycemic Control Retrospective Studies

More Related Videos

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

Related Experiment Videos

Last Updated: Jun 14, 2025

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

Area of Science:

Endocrinology
Medical Devices
Diabetes Technology

Background:

The Glucose Management Indicator (GMI) is a metric derived from continuous glucose monitoring (CGM) data used to estimate HbA1c.
Existing GMI calculations may not be universally applicable across different CGM systems, potentially leading to inaccuracies.

Purpose of the Study:

To develop and validate device-specific GMI equations for the Guardian 3 (G3) and Guardian 4 (G4) CGM sensors.
To compare the performance of these new GMI equations against the original GMI.
To analyze the glycaemic gap (HbA1c - GMI) and its relationship with HbA1c for different CGM systems.

Main Methods:

An observational study involving adult patients with type 1 diabetes using G3 and G4 CGM devices.
Linear mixed models were used to estimate HbA1c from CGM-derived mean glucose for both G3 and G4 sensors.
Regression analysis and Bland-Altman plots were employed to compare device-specific GMI estimates and their residuals (gaps) with the original GMI.

Main Results:

The study included 120 adult type 1 diabetes patients (90 G3, 30 G4) with 194 measurement points.
For both G3 and G4 sensors, the original GMI significantly underestimated HbA1c at higher ranges.
The GMI overestimated HbA1c in the lower range for the G4 sensor, and device-specific GMI gaps were smaller than the original GMI gap.

Conclusions:

Device-specific GMI equations for Guardian 3 and 4 sensors can mitigate the risk of clinically significant HbA1c under- and overestimation.
Implementing tailored GMI equations can enhance the accuracy of glycaemic assessment, leading to improved clinical decision-making for type 1 diabetes management.